AARTI PHARMALABS meets investors on May 28

AARTI PHARMALABS LIMITED has scheduled a meeting with investors and analysts to discuss the ordinary course of business. The interaction is set to take place on Thursday, May 28, 2026, as part of the 360 ONE Capital Conference - Trinity 2026.

The company will engage in both one-on-one and group meetings during the event. The session will be conducted via physical mode. AARTI PHARMALABS noted that the schedule may be subject to changes depending on the analysts, institutional investors, or the company.

Event Details

The following table outlines the specifics of the upcoming conference:

Day and Date	Name of the Event	Mode
Thursday, May 28, 2026	360 ONE Capital Conference - Trinity 2026	Physical Mode

The company clarified that no unpublished price sensitive information pertaining to the company will be shared during the said meeting. The intimation was made to the stock exchanges in compliance with Regulation 30 of the SEBI (LODR) Regulations 2015.

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
+3.12%	-2.66%	-18.40%	-10.33%	-31.38%	+116.91%

Aarti Pharmalabs Limited has informed the stock exchanges that the Board of Directors meeting, originally scheduled for Monday, May 18, 2026, has been postponed and rescheduled to Monday, May 25, 2026. The postponement intimation was issued on May 14, 2026, in compliance with Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, referencing the earlier intimation dated May 11, 2026.

Revised Board Meeting Details

The rescheduled Board meeting will address the same agenda items as originally planned. The following table summarises the updated meeting details:

Parameter:	Details
Original Meeting Date:	Monday, May 18, 2026
Revised Meeting Date:	Monday, May 25, 2026
Regulatory Reference:	Regulation 29, SEBI (LODR) Regulations, 2015
Agenda Item 1:	Audited Financial Results for Q4 and FY ended March 31, 2026
Agenda Item 2:	Consider and recommend Final Dividend, if any, for FY ended March 31, 2026
Postponement Intimation Date:	May 14, 2026

Financial Results and Dividend Consideration

The Board will consider and approve the audited financial results of the company for the quarter and financial year ended March 31, 2026, after these results are reviewed by the Audit Committee of the Board. Additionally, the Board will deliberate on whether to recommend a final dividend for the financial year ended March 31, 2026, subject to applicable approvals.

Trading Window Closure

In accordance with the SEBI (Prohibition of Insider Trading) Regulations, 2015, the Trading Window for dealing in the securities of Aarti Pharmalabs had been closed from April 01, 2026. Following the postponement of the Board meeting, the Trading Window shall now remain closed until 48 hours after the declaration of the financial results, i.e., till May 27, 2026.

The postponement intimation was signed by Jeevan Mondkar, Company Secretary and Legal Head (ICSI M. No. A22565), on behalf of Aarti Pharmalabs Limited.